About this Series

Hodgkin lymphoma (HL) most often strikes two separate age groups: people between 15 and 30 years of age and those over 55. Significant progress in the management of patients with classical HL has been achieved over the past few decades, yet relapse occurs in 10%-20% of patients with favorable features and early-stage disease, and up to 30% of patients with advanced-stage disease.

In this three-part series, hematologists at the University of Nebraska explore the most promising options for the treatment of relapsed/refractory classical HL. Topics include strategies for maximizing the success of high-dose chemotherapy and autologous stem cell transplantation and the use of brentuximab vedotin, immunotherapies, and combination therapies. The risks and toxicities for patients undergoing such treatments and the impact of age on treatment choice are also considered.

Show More

Who's Who
{{#each bp-whos-who.people}}
{{{name}}} {{{addComma prof}}}
{{#if disclosureTitle }} Disclosure
More on Hodgkin Lymphoma (cHL)